N1-benzenesulfonyl-2-pyrazoline hybrids in neurological disorders

dc.contributor.authorTripathi, Avinash C.
dc.contributor.authorUpadhyay, Savita
dc.contributor.authorPaliwal, Sarvesh
dc.contributor.authorSaraf, Shailendra K.
dc.date.accessioned2018-06-15T06:01:11Z
dc.date.available2018-06-15T06:01:11Z
dc.date.issued2018-01-19
dc.description.abstractA novel series of 1,3,5-trisubstituted-2-pyrazolines (5a-5t) was prepared via Claisen Schmidt condensation, followed by heterocyclization with hydrazine hydrate, substitution of N1 hydrogen of 2-pyrazoline nucleus with 4-chlorobenzenesulfonylchloride, applying conventional and green chemistry approaches. Among the two, microwave assisted organic synthesis (MAOS) emerged as a better synthetic tool in terms of faster reaction rate and high yield. Various physicochemical and spectral studies were conducted to characterize the synthesized derivatives including- IR, Mass, 1H-NMR, 13C-NMR and elemental analysis. During pharmacological evaluation, compound 5b showed excellent anti-anxiety activity and compound 5k exhibited the best antidepressant effect at the tested doses, 50 and 100 mg/kg b.w., being comparable to diazepam and imipramine, respectively. The docking experiments confirmed the probable mechanism of neuropharmacological action, showing excellent affinity towards MAO-A target protein, which was also evidenced from some of the key interactions with binding site residues Ala68, Tyr69 and Phe352. Furthermore, complimentary in silico pharmacokinetic recital without any potential risk of neurotoxicity (as evaluated by rotarod and actophotometer tests), or carcinogenicity, mutagenicity, reproductive toxicity, acute toxicity and irritancy (as predicted by LAZAR and OSIRIS programs) signified their probable use in depression and anxiety disorders.en
dc.identifier.issn1611-2156
dc.identifier.urihttp://hdl.handle.net/2003/36914
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-18913
dc.language.isoen
dc.relation.ispartofseriesEXCLI Journal;Vol. 17 2018
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject2-Pyrazolinesen
dc.subjectAntidepressant and anti-anxietyen
dc.subjectNeurotoxicityen
dc.subjectMicrowave synthesisen
dc.subjectMolecular dockingen
dc.subjectIn silico ADME predictionen
dc.subject.ddc610
dc.titleN1-benzenesulfonyl-2-pyrazoline hybrids in neurological disordersen
dc.title.alternativesyntheses, biological screening and computational studiesen
dc.typeText
dc.type.publicationtypearticle
dcterms.accessRightsopen access
eldorado.dnb.deposittruede
eldorado.dnb.zdberstkatid2132560-1
eldorado.secondarypublicationtrue

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
Saraf19012018_proof.pdf
Größe:
783.7 KB
Format:
Adobe Portable Document Format
Beschreibung:
DNB

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
license.txt
Größe:
4.85 KB
Format:
Item-specific license agreed upon to submission
Beschreibung: